Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Preparation of Nanoliposomes Containing Her2/Neu (P5+435) Peptide and Evaluation of Their Immune Responses and Anti-Tumoral Effects As a Prophylactic Vaccine Against Breast Cancer Publisher Pubmed



Naghibi L1, 2 ; Yazdani M1 ; Momtaziborojeni AA3 ; Razazan A4 ; Shariat S1 ; Mansourian M1, 2 ; Arab A1, 2, 5 ; Barati N6 ; Arabsalmani M1 ; Abbasi A1 ; Saberi Z1 ; Badiee A1, 2 ; Jalali SA7 ; Jaafari MR1, 2, 5
Authors

Source: PLoS ONE Published:2020


Abstract

HER2/neu is an immunogenic protein inducing both humoral and cell-mediated immune responses. The antigen-specific cytotoxic T lymphocytes (CTLs) are the main effector immune cells in the anti-tumor immunity. To induce an effective CTL specific response against P5+435 single peptide derived from rat HER2/neu oncogene, we used a liposome delivery vehicle. In vivo enhancement of liposome stability and intracytoplasmic delivery of peptides are the main strategies which elevate the liposome-mediated drug delivery. Liposomes containing high transition temperature phospholipids, such as DSPC, are stable with prolonged in vivo circulation and more accessibility to the immune system. Incorporation of DOPE phospholipid results in the effective delivery of peptide into the cytoplasm via the endocytotic pathway. To this end, the P5+435 peptide was linked to Maleimide-PEG2000-DSPE and coupled on the surface of nanoliposomes containing DSPC: DSPG: Cholesterol with/without DOPE. We observed that mice vaccinated with Lip-DOPE-P5+435 formulation had the highest number of IFN-γ- producing CTLs with the highest cytotoxic activity that consequently led to significantly smallest tumor size and prolonged survival rate in the TUBO mice model. In conclusion, our study indicated that the liposomal form of P5+435 peptide containing DOPE can be regarded as a promising prophylactic anti-cancer vaccine to generate potent antigen-specific immunity. © 2020 Naghibi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Other Related Docs
13. Development of Nano-Carriers for Leishmania Vaccine Delivery, Expert Opinion on Drug Delivery (2020)
16. Liposome-Targeted Delivery for Highly Potent Drugs, Artificial Cells# Nanomedicine and Biotechnology (2017)
20. Delivery Systems for Leishmania Vaccine Development, Expert Review of Vaccines (2016)